InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,557.75
(
-1.60%
)
US TECH 100
18,632.40
(
-2.20%
)
Dow Jones
41,082.10
(
-1.16%
)
Brent Oil
73.59
(
-4.67%
)
Bitcoin
57,943.36
(
-1.99%
)
Post# of 253012
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 837
Posts 120354
Boards Moderated 18
Alias Born 09/05/2002

DewDiligence

Member Level

Re: ocyanblue post# 34415

Monday, 09/25/2006 1:41:27 PM

Monday, September 25, 2006 1:41:27 PM

Post# of 253012
> GPCB – I hope you are not saying that he delayed giving Satraplatin to placebo patients after progression to improve the chance of getting survival significance. This would be unethical to say the least and possibly illegal.<

No—of course not! What GPCB did was to increase the number of PFS events in the unblinding trigger beyond the value originally specified in the SPA.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up